SG190952A1 - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents

Compositions and methods for treating amyloid plaque associated symptoms Download PDF

Info

Publication number
SG190952A1
SG190952A1 SG2013042288A SG2013042288A SG190952A1 SG 190952 A1 SG190952 A1 SG 190952A1 SG 2013042288 A SG2013042288 A SG 2013042288A SG 2013042288 A SG2013042288 A SG 2013042288A SG 190952 A1 SG190952 A1 SG 190952A1
Authority
SG
Singapore
Prior art keywords
methods
compositions
associated symptoms
amyloid plaque
plaque associated
Prior art date
Application number
SG2013042288A
Other languages
English (en)
Inventor
David Holtzman
Jungsu Kim
Hong Jiang
Adam Eltorai
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of SG190952A1 publication Critical patent/SG190952A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG2013042288A 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms SG190952A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US201161548542P 2011-10-18 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
SG190952A1 true SG190952A1 (en) 2013-07-31

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013042288A SG190952A1 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Country Status (14)

Country Link
US (2) US20140037638A1 (https=)
EP (1) EP2646053A4 (https=)
JP (1) JP2014502276A (https=)
KR (1) KR20140017513A (https=)
CN (1) CN103338786A (https=)
AU (1) AU2011336360A1 (https=)
BR (1) BR112013013723A2 (https=)
CA (1) CA2819679A1 (https=)
MX (1) MX2013006116A (https=)
NZ (1) NZ611614A (https=)
RU (1) RU2013130002A (https=)
SG (1) SG190952A1 (https=)
WO (1) WO2012075422A2 (https=)
ZA (1) ZA201303996B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
US10830775B2 (en) 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
WO2017192711A1 (en) * 2016-05-03 2017-11-09 University Of South Florida Compositions and methods of modulating abeta protein
EP3532034A4 (en) * 2016-10-28 2020-12-02 Washington University ANTI-APOE ANTIBODY
WO2019018402A2 (en) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
CA3141988A1 (en) * 2019-05-28 2020-12-03 The General Hospital Corporation Apoe antibodies, fusion proteins and uses thereof
US20240400659A1 (en) * 2021-10-19 2024-12-05 Bioatla, Inc. Conditionally active proteins for neurodegenerative diseases
CN120787237A (zh) * 2022-11-30 2025-10-14 明尼苏达大学董事会 自然杀伤细胞接合剂
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
KR20060120161A (ko) * 2003-11-28 2006-11-24 아스트라제네카 아베 항체
WO2005094846A1 (ja) * 2004-03-30 2005-10-13 Renomedix Institute Inc. プリオン病治療剤およびその製造方法
CA2643048A1 (en) * 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
JP5632582B2 (ja) * 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2011109246A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Also Published As

Publication number Publication date
AU2011336360A1 (en) 2013-07-04
KR20140017513A (ko) 2014-02-11
JP2014502276A (ja) 2014-01-30
EP2646053A2 (en) 2013-10-09
RU2013130002A (ru) 2015-01-10
NZ611614A (en) 2015-07-31
US20160355581A1 (en) 2016-12-08
US20140037638A1 (en) 2014-02-06
ZA201303996B (en) 2015-10-28
BR112013013723A2 (pt) 2019-09-24
WO2012075422A3 (en) 2012-10-04
MX2013006116A (es) 2013-10-17
CA2819679A1 (en) 2012-06-07
CN103338786A (zh) 2013-10-02
WO2012075422A2 (en) 2012-06-07
EP2646053A4 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
SG190952A1 (en) Compositions and methods for treating amyloid plaque associated symptoms
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201590247A1 (ru) Антитела к siglec-15
MX2011009690A (es) Métodos y composiciones para trastornos relacionados con la proliferación celurar.
NI201200171A (es) Anticuerpos hacia gdf8 humano
CO6571886A2 (es) Antagonistas de pcsk9
UA109271C2 (uk) Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
EP2608778A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF BONE DEFECTS
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
PT2621520E (pt) Composições de colagenase g e colagenase h para o tratamento de doenças que envolvem alterações de colagénio
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
GB201109238D0 (en) Antibodies
PH12015501360A1 (en) Bmp-6 antibodies
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
MX2014006337A (es) Composiciones de proteina del gen 3 de bacteriofago y sus usos como agentes de union amiloides.